Compounded Peptides in 2026: What the FDA Panel Changed, and What a Non-Sterile Pharmacy Can Make Today

The short version: on July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides for the 503A bulks list. That vote changed the conversation and changed nothing at the pharmacy counter. Until the FDA writes and finalizes a rule, those six remain off limits. What a non-sterile pharmacy can prepare today is a shorter, more useful list, and this post is that list.

KeyPoints

• The July 2026 PCAC vote recommended BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. It rejected DSIP. FDA staff had recommended against all seven.
• A recommendation is not authorization. None of the six is legal to compound until proposed and final rulemaking is complete.
• GHK-Cu left the FDA's Category 1 list in April 2026 (nomination withdrawn), with a PCAC review due before February 2027. Topical GHK-Cu can still be prescribed for an individual patient.
• Peptides that are components of approved drugs, such as PT-141 and oxytocin, follow the ordinary patient-specific 503A rules. Our PT-141 formulas are Rx-only, prescriber-directed.
• We prepare non-sterile forms only: creams, troches, capsules, nasal sprays. No injectables, ever.

EndKeyPoints

What happened in July 2026

The Pharmacy Compounding Advisory Committee is the outside panel the FDA consults before adding a substance to the 503A bulks list. That list names the ingredients a compounding pharmacy may use even though they are not components of an approved drug. Over two days the committee reviewed seven peptides that the FDA had pulled from its "Category 2" holding list earlier in the year. The agency's own reviewers recommended against listing any of them, citing thin human safety data. The committee disagreed on six.

What the vote did not do

It did not add anything to the list. The FDA has said it will open notice-and-comment rulemaking, which means a proposed rule, a public comment period, and a final rule. Attorneys who follow the bulks list put that at many months to two years. The final rule may also name specific routes of administration. For a pharmacy that only prepares non-sterile forms, the route language matters more than the headline. An oral or topical listing for KPV would be usable. An injectable-only listing for TB-500 would not.

Two more dates to watch. In April 2026 the FDA removed twelve peptides from Category 2 and scheduled the July meeting. And the agency has committed to consulting the committee on GHK-Cu before the end of February 2027.

GHK-Cu: still prescribed, footing changed

GHK-Cu (copper tripeptide) sits differently. On April 22, 2026 the FDA removed GHK-Cu for non-injectable routes from Category 1, and the injectable form from Category 2, because the nominations were withdrawn; the agency will take it to its advisory committee before the end of February 2027. Copper tripeptide-1 remains a lawful cosmetic ingredient, and a prescriber can still write for a topical GHK-Cu preparation for an individual patient. What we do not do is describe it as a treatment. Our GHK-Cu copper peptide cream is compounded to the prescriber's order; the strength and base are set by the prescriber.

Peptides that were never in question

Some peptides are components of FDA-approved drugs, which puts them on firmer ground than anything on the bulks list. Two appear in our formulary:

• Bremelanotide (PT-141): Rx-only, prescriber-directed. See the Rx-only listings for the PT-141 troche and the tadalafil + oxytocin + PT-141 dissolvable; prescribers sign in for details.
• Oxytocin, prepared as a nasal form, prescriber-directed.

The rule that governs these is the "essentially a copy" provision. A compounded version must differ from the commercial product in a way the prescriber documents as clinically significant for that patient. A different route, a different strength, or the removal of an excipient all qualify. That documentation is the prescriber's; our job is the preparation.

What we do not and will not compound

• Any of the six recommended peptides, including BPC-157, KPV and TB-500. We do not offer them.
• Injectables of any kind. We hold no sterile (USP <797>) capability and do not intend to.
• Peptides the FDA has removed from consideration or that remain in regulatory limbo, including Selank, melanotan II, LL-37 and DiHexa.
• Anything sold as a "research chemical." If it is not pharmaceutical grade with a certificate of analysis, it does not enter the building.

The non-peptide formulas prescribers are asking for most

The peptide headlines pull attention from the formulas that account for most of the actual prescriptions in 2026. All of these are non-sterile, all are in our formulary, and all require a prescription.

• Low-dose oral minoxidil for hair loss, at strengths not sold commercially.
• Enclomiphene capsules: Rx-only, prescriber-directed.
• NAD+ precursors in sublingual and oral forms.
• Methylene blue capsules, with the SSRI interaction screened by the prescriber.
• Low-dose naltrexone, one of the most widely requested compounded medications.
• Topical sirolimus for prescriber-directed dermatology use.
• Tranexamic acid, topical and oral, for melasma protocols.

Prescribers can search all of them, with typical strength ranges, in the Prescriber Portal after signing in to the Prescriber Portal.

How to stay current

We read the FDA's compounding pages and the committee dockets so you do not have to. When a proposed rule for the six peptides publishes, when the GHK-Cu review lands, and when any final rule specifies routes, this post gets a dated update at the top. An update here is a status note, not a new offering. Until then, treat any offer of compounded BPC-157 the way you would treat any other product that skipped the rules.

Sources

• FDA: July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee
• FDA briefing document for the PCAC peptide review
• AJMC: FDA panel backs 6 peptides for compounding
• McDermott: PCAC backs majority of peptides in two-day public meeting
• Orrick: FDA removes 12 peptides from Category 2 and schedules PCAC meetings (April 2026)
• FDA: bulk drug substances nominated for use in compounding (interim category list)